ADARx Pharmaceuticals, Inc. ADRX
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -33.90%
- 1 year
- -33.90%
5D -2.15 (-14.22%)
- Market cap
- 1.42B
- Revenue (ttm)
- 6.79M
- EPS (ttm)
- -6.75
- Shares out
- 111.19M
- Forward P/E
- -8.27
- YTD return
- -33.90%
- 1-year return
- -33.90%
- 50-day average
- 16.79
- Volume
- 708.83K
- Avg volume
- 649.17K
- Open
- 14.03
- Previous close
- 14.16
- Day's range
- 12.66 – 14.86
- 52-week range
- 12.79 – 20.64
- Analysts
- Strong Buy
- Price target
- 33.75 (+163.9%)
Key statistics
- 200-day average
- 16.79
- Enterprise value
- 679.95M
- Price / sales
- 208.66
- Revenue growth
- 42.60%
- Total cash
- 901.01M
- Total debt
- 6.46M
Fundamental scorecard
5 of 25 checks passed on ADRX’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Dec 30, 2026 | -0.40 | -1.74 | -1.34 | -335.00% |
| Sep 2, 2026 | Sep 30, 2026 | -0.82169 | -2.27 | -1.45 | -176.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | TD Cowen | init | — | Buy |
| Oct 20, 2026 | JP Morgan | init | — | Overweight |
| Oct 20, 2026 | UBS | init | — | Buy |
| Oct 20, 2026 | Morgan Stanley | init | — | Overweight |
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adarx.com
News
Your note
Sign in to keep a note on ADRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHIMOVITS EREZ | Director | Purchase | Sep 27, 2026 | 0 |
| GEORGE SIMEON J. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| LAV BIOSCIENCES FUND V LP | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 27, 2026 | 0 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| SR ONE CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 21.77% | 24,205,789 | 308.38M | Sep 29, 2026 |
| SR One Capital Management, LP | 8.94% | 9,936,661 | 126.59M | Sep 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 6.05% | 6,728,970 | 85.73M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 3.70% | 4,116,452 | 52.44M | Sep 29, 2026 |
| FMR, LLC | 3.28% | 3,646,090 | 46.45M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 2.60% | 2,894,396 | 36.87M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.92% | 3,246,801 | 41.36M | Sep 29, 2026 |
| Fidelity Contrafund | 0.42% | 467,700 | 5.96M | Sep 29, 2026 |
| AB CAP FUND, INC.-AB Small Cap Growth Portfolio | 0.39% | 430,729 | 5.49M | Sep 29, 2026 |
| AB DISCOVERY GROWTH FUND, INC. | 0.38% | 427,316 | 5.44M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.36% | 400,000 | 5.10M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Blue Chip Growth Fund | 0.30% | 328,200 | 4.18M | Sep 29, 2026 |
